solute carrier family 25 member 37Genealiases: HT015 · MFRN · MFRN1 · MSCP
Q-omics provides the consensus-scored SLC25A37 profile across patient tissues and cancer cell-line models. SLC25A37 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC25A37 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, SLC25A37 RNA expression shows 18,574 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KIRP, and THYM as cancer lineages where SLC25A37 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC25A37 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC25A37 survival associations across molecular data types. SLC25A37 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC25A37 RNA expression–survival associations across cancer types. High SLC25A37 expression shows unfavorable associations in KIRC, STAD, LGG, KICH, MESO and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC25A37 RNA expression.
This table summarizes SLC25A37 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLC25A37. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC25A37 shows lower tumor expression in BRCA and higher tumor expression in KIRP, THCA, KIRC, HNSC and LUAD. The KIRP box plot shows higher SLC25A37 RNA expression in tumor versus normal tissue (log2 FC = +1.431, t-test p < 0.001).
This table shows molecular features associated with SLC25A37 in patient tissues and cancer cell lines. In patient samples, SLC25A37 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC25A37 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
